{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T14:00:01Z","timestamp":1719237601562},"reference-count":25,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.22042","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T22:11:23Z","timestamp":1679955083000},"page":"49-57","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases"],"prefix":"10.3960","volume":"63","author":[{"given":"Emiko","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imai","sequence":"additional","affiliation":[{"name":"Pathology Division, Mie University Hospital, Tsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,"},{"name":"Center for Clinical Pathology, Fujita Health University Hospital, Toyoake, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan,"},{"name":"Division of Hematology, Department of Medicine, Keio University School of\u2028Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Hamamatsu University Hospital, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Hamamatsu University Hospital, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Shimauchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Handa City Hospital, Handa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ansell SM, Lesokhin AM, Borrello I <i>et al.<\/i> PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 372: 311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Armand P, Shipp MA, Ribrag V <i>et al.<\/i> Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34: 3733-3739.","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ilcus C, Bagacean C, Tempescul A <i>et al.<\/i> Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets Ther. 2017; 10: 2349-2363.","DOI":"10.2147\/OTT.S133385"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Younes A, Santoro A, Shipp M <i>et al.<\/i> Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17: 1283-1294.","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Chen R, Zinzani PL, Fanale MA <i>et al.<\/i> Phase II Study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35: 2125-2132.","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chen BJ, Chapuy B, Ouyang J <i>et al.<\/i> PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19: 3462-3473.","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Panjwani PK, Charu V, DeLisser M <i>et al.<\/i> Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018; 71: 91-99.","DOI":"10.1016\/j.humpath.2017.10.029"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kantekure K, Yang Y, Raghunath P <i>et al.<\/i> Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides. Am J Dermatopathol. 2012; 34: 126-128.","DOI":"10.1097\/DAD.0b013e31821c35cb"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Gerbe A, Alame M, Dereure O <i>et al.<\/i> Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior. Virchows Arch. 2019; 475: 163-174.","DOI":"10.1007\/s00428-019-02570-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Takahashi E, Tsuchida T, Baba S <i>et al.<\/i> Enhanced PD\u2010L1 expression on tumor cells in primary cutaneous large T\u2010cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases. Pathol Int. 2020; 70: 804-811.","DOI":"10.1111\/pin.13000"},{"key":"11","unstructured":"11 Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, IARC Press. 2017."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Takahashi E, Asano N, Li C <i>et al.<\/i> Nodal T\/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology. 2008; 52: 585-596.","DOI":"10.1111\/j.1365-2559.2008.02997.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 van Dongen JJM, Langerak AW, Br\u00fcggemann M <i>et al.<\/i> Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17: 2257-2317.","DOI":"10.1038\/sj.leu.2403202"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Yamashita D, Shimada K, Kohno K <i>et al.<\/i> PD\u2010L1 expression on tumor or stromal cells of nodal cytotoxic T\u2010cell lymphoma: A clinicopathological study of 50 cases. Pathol Int. 2020; 70: 513-522.","DOI":"10.1111\/pin.12950"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Carey CD, Gusenleitner D, Lipschitz M <i>et al.<\/i> Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017; 130: 2420-2430.","DOI":"10.1182\/blood-2017-03-770719"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Green MR, Monti S, Rodig SJ <i>et al.<\/i> Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116: 3268-3277.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Roemer MGM, Advani RH, Ligon AH <i>et al.<\/i> PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34: 2690-2697.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Chapuy B, Roemer MGM, Stewart C <i>et al.<\/i> Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; 127: 869-881.","DOI":"10.1182\/blood-2015-10-673236"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Hong L, Negrao MV, Dibaj SS <i>et al.<\/i> Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC. J Thorac Oncol. 2020; 15: 1449-1459.","DOI":"10.1016\/j.jtho.2020.04.026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Li Y, Vennapusa B, Chang CW <i>et al.<\/i> Prevalence study of PD-L1 SP142 assay in metastatic triple-negative breast cancer. Appl Immunohistochem Mol Morphol. 2021; 29: 258-264.","DOI":"10.1097\/PAI.0000000000000857"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Madore J, Vilain RE, Menzies AM <i>et al.<\/i> PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015; 28: 245-253.","DOI":"10.1111\/pcmr.12340"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Sakakibara A, Inagaki Y, Imaoka E <i>et al.<\/i> Divergence and heterogeneity of neoplastic PD\u2010L1 expression: two autopsy case reports of intravascular large B\u2010cell lymphoma. Pathol Int. 2019; 69: 148-154.","DOI":"10.1111\/pin.12757"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 van Doorn R, Van Haselen CW, van Voorst Vader PC <i>et al.<\/i> Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136: 504-510.","DOI":"10.1001\/archderm.136.4.504"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Woo DK, Jones CR, Vanoli-Storz MN <i>et al.<\/i> Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009; 145: 667-674.","DOI":"10.1001\/archdermatol.2009.74"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Liu HL, Hoppe RT, Kohler S <i>et al.<\/i> CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003; 49: 1049-1058.","DOI":"10.1016\/S0190-9622(03)02484-8"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/1\/63_22042\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:18:17Z","timestamp":1715318297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/1\/63_22042\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22042","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"22042"}}